For research use only. Not for therapeutic Use.
Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide CGRP receptor antagonist with potential for acute research in migraine. CGRP is an important trigger in migraine pathophysiology[1][2][3].
Catalog Number | I044522 |
CAS Number | 1337918-83-8 |
Synonyms | N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1H-quinolin-3-yl)piperidine-1-carboxamide |
Molecular Formula | C36H46N8O3 |
Purity | ≥95% |
InChI | InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1 |
InChIKey | JJVAPHYEOZSKJZ-JGCGQSQUSA-N |
SMILES | CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O |
Reference | [1]. Leonard KA, et al. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2020 Mar 26;63(6):2915-2929. [2]. Gene M Dubowchik, et al. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. [3]. Capi M, De Angelis V, De Bernardini D, et al. Zavegepant[M]//Novel Synthetic Drugs in Migraine. Cham: Springer International Publishing, 2022: 67-72. |